Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 9/20 | 0.54 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22867360 | 0.72 | MAP2K1 (0.37) | HSD17B2HSD17B1MEN1MAPTKMT2A | |
| SCHEMBL22867945 | 0.72 | HSD17B1 (0.54) | HSD17B2HSD17B1KDM4EBTKHPGD | |
| SCHEMBL3083467 | 0.72 | HSD17B2 (0.36) | HSD17B2HSD17B1MEN1MAPTKMT2A | |
| SCHEMBL24932982 | 0.72 | HSD17B1 (0.36) | HSD17B2HSD17B1 | |
| SCHEMBL22867739 | 0.72 | HSD17B2 (1.00) | HSD17B2HSD17B1 | |
| SCHEMBL27903406 | 0.70 | PTGDR2 (0.55) | KDM4EMEN1MAPTKMT2ACAMKK2 | |
| SCHEMBL24933633 | 0.70 | PARP10 (0.53) | HPGD | |
| SCHEMBL22868089 | 0.69 | HSD17B1 (0.58) | HSD17B2HSD17B1 | |
| SCHEMBL5531782 | 0.68 | KDM4E (0.42) | HSD17B2HSD17B1KDM4EMEN1MAPT | |
| SCHEMBL5527850 | 0.68 | KDM4E (0.42) | HSD17B2HSD17B1KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3994125-B1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| EP-3994125-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-2021003295-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | HSD17B2 5/4885HSD17B1 3/4885KDM4E 3109/4885 |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | HSD17B2 5/4885HSD17B1 3/4885KDM4E 3109/4885 |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | HSD17B3, HSD17B11, HSD17B1 | HSD17B2 5/4885HSD17B1 3/4885KDM4E 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.